1. Figure 1 Platelet receptors and available pharmaceutical options
Figure 1 | Platelet receptors and available pharmaceutical options. Current and emerging antiplatelet therapies are based on blockade of the thromboxane pathway, inhibition of platelet activation, and serotonin receptor 2A antagonism. 5-HT2A, serotonin receptor 2A; COX, cyclooxygenase; GP, glycoprotein; PAR, protease-activated receptor; TP, thromboxane prostanoid receptor; TXS, thromboxane A2 synthase; vWF, von Willebrand factor. Reprinted from Franchi, F. et al. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12 (10), 30–47 (2015), with permission from Macmillan Publishers Limited.
Reprinted from Franchi, F. et al. Novel antiplatelet agents in acute coronary syndrome.
Nat. Rev. Cardiol. 12 (10), 30–47 (2015), with permission from Macmillan Publishers Limited
Serebruany, V. & Golukhova, E. (2017) Aspirin in the elderly — tailored approaches ahead?
Nat. Rev. Cardiol. doi: /nrcardio